Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07210632 · ClinicalTrials.gov registry record · Early Phase 1
Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)
A Early Phase 1 study, sponsored by Eben Rosenthal.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 38
- Enrollment target
NCT07210632: Recruiting Early Phase 1 study, sponsored by Eben Rosenthal.
NCT07210632 is a Early Phase 1 study that is actively recruiting participants, run by Eben Rosenthal. The registered enrollment target is 38 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (28% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07210632, a Early Phase 1 study, is actively recruiting participants, sponsored by Eben Rosenthal.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
High-grade gliomas (HGGs) are among the most aggressive and treatment-resistant brain tumors. Immunotherapy with checkpoint inhibitors like nivolumab has shown promise, but its efficacy remains variable and poorly understood in this patient population. This clinical trial investigates a novel imaging-enabled formulation of nivolumab-IRDye800 (nivo800) which incorporates a near-infrared (NIR) fluorescent dye to enable real-time visualization of drug distribution within tumor tissue.
Primary Outcome
As defined by the number of Grade ≥ 2 Adverse Events (AEs) determined that are clinically significant and considered definitely or probably related to nivo800. Safety data will be summarized by grade, severity, and type.
Interventions
- DRUG Nivolumab
- DRUG Nivolumab-IRDye800
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2026-03-27 |
| Est. Completion | 2031-03-30 |
| Phase | Early Phase 1 |
What NCT07210632 shows while recruiting
NCT07210632 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (28% lower).
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT07210632 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07210632 about?
NCT07210632 is a clinical study titled "Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)". High-grade gliomas (HGGs) are among the most aggressive and treatment-resistant brain tumors. Immunotherapy with checkpoint inhibitors like nivolumab has shown promise, but its efficacy remains variable and poorly understood in this patient population. This clinical trial investigates a novel imagin...
What is the current status of trial NCT07210632?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 38 participants. The study started on 2026-03-27. Estimated completion is 2031-03-30.
What interventions are being tested in trial NCT07210632?
The interventions under investigation include: Nivolumab (DRUG), Nivolumab-IRDye800 (DRUG).
Who is sponsoring clinical trial NCT07210632?
This trial is sponsored by Eben Rosenthal, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07210632's enrollment target sits among peer trials
38 699th of 2000 higher than 1,299 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI